CIK 0001006281 · Non-accelerated filer<br>Smaller reporting company
Protalix BioTherapeutics, Inc.
Sign in to watch- Ticker
- PLX
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 650643773
- Phone
- 201-696-9345
- Business address
- 2 UNIVERSITY PLAZA, SUITE 100, HACKENSACK, NJ, 07601
- Former names
- ORTHODONTIX INC, EMBASSY ACQUISITION CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2009-04-17 | Aviezer David President & CEO | Sale | −10,000 | $2.56 | $26K | 0 |
| 2009-04-16 | Aviezer David President & CEO | Sale | −6,700 | $2.50 | $17K | 0 |
| 2009-03-13 | Maimon Yossi VP, Chief Financial Officer | Option exercise | +39,800 | $0.97 | $39K | 0 |
| 2009-03-13 | Maimon Yossi VP, Chief Financial Officer | Shares withheld for taxes | −17,910 | $2.16 | $39K | 0 |
| 2009-03-13 | Maimon Yossi VP, Chief Financial Officer | Sale | −7,500 | $2.23 | $17K | 0 |
| 2009-03-13 | Maimon Yossi VP, Chief Financial Officer | Option exercise · Stock Options (Right to Buy) | −39,800 | 493,996 | ||
| 2009-03-13 | Shaaltiel Yoseph Executive VP, R&D | Sale | −8,300 | $2.18 | $18K | 1,493,754 |
| 2009-03-12 | Maimon Yossi VP, Chief Financial Officer | Sale | −32,241 | $2.22 | $72K | 0 |
| 2009-03-11 | Maimon Yossi VP, Chief Financial Officer | Sale | −8,849 | $2.30 | $20K | 0 |
| 2009-02-25 | Maimon Yossi VP, Chief Financial Officer | Grant or award · Stock Options (Right to Buy) | +50,000 | 50,000 | ||
| 2009-02-25 | Aviezer David President & CEO | Grant or award · Stock Options (Right to Buy) | +100,000 | 100,000 | ||
| 2009-02-25 | Shaaltiel Yoseph Executive VP, R&D | Grant or award · Stock Options (Right to Buy) | +50,000 | 50,000 | ||
| 2009-02-25 | Almon Einat Brill VP, Product Development | Grant or award · Stock Options (Right to Buy) | +50,000 | 50,000 | ||
| 2008-10-10 | FROST PHILLIP MD ET AL 10% owner | Purchase | +900 | $1.62 | $1K | 9,777,173 |
| 2008-10-10 | FROST PHILLIP MD ET AL 10% owner | Purchase | +600 | $1.63 | $978 | 9,777,773 |
| 2008-10-10 | FROST PHILLIP MD ET AL 10% owner | Purchase | +2,500 | $1.64 | $4K | 9,780,273 |
| 2008-10-10 | FROST PHILLIP MD ET AL 10% owner | Purchase | +1,000 | $1.66 | $2K | 9,781,273 |
| 2008-05-12 | Almon Einat Brill VP, Product Development | Sale | +41,427 | $2.75 | $114K | 0 |
| 2008-05-11 | Almon Einat Brill VP, Product Development | Option exercise | +48,370 | $0.40 | $19K | 48,370 |
| 2008-05-11 | Almon Einat Brill VP, Product Development | Shares withheld for taxes | −6,943 | $2.78 | $19K | 41,427 |
Page 30 of 33 · 654 trades